Identification of a new JNK inhibitor targeting the JNK-JIP interaction site.
D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism*; D000818:Animals; D001667:Binding, Competitive; D056486:Chemical and Drug Induced Liver Injury; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy; D004146:Dioxanes / Q000494:pharmacology*; D007333:Insulin Resistance; D048031:JNK Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008107:Liver Diseases / Q000517:prevention & control; D051379:Mice; D018716:Molecular Mimicry; D010766:Phosphorylation / Q000187:drug effects; D011485:Protein Binding; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D015398:Signal Transduction; D013844:Thiazoles / Q000494:pharmacology*
C576038:4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2,4-dihydro-5-((5-nitro-2-thiazolyl)thio)-3H-1,2,4-triazol-3-one; D048868:Adaptor Proteins, Signal Transducing; D004146:Dioxanes; C490666:MAPK8IP1 protein, human; D047428:Protein Kinase Inhibitors; D013844:Thiazoles; D048031:JNK Mitogen-Activated Protein Kinases